Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs represent a distinct category of tumors characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is useful not only for the diagnosis but also for targeted therapy of this disease. Imatinib, a tyrosine kinase inhibitor, is widely used in advanced and metastatic GISTs. This agent revolutionized the treatment strategy of advanced disease and is being tested in the neoadjuvant and adjuvant settings with encouraging results. New therapeutic agents like sunitinib have now been approved, enriching the treatment scenario for imatinib-resistant GISTs. The present review reports on the peculiar characteristics of this disease through its biology and molecular patterns, focusing on the predictive value of KIT mutations and their correlation with clinical outcome as well as on the activity of and resistance to approved targeted drugs.
RubinB.P.. Gastrointestinal stromal tumours: an update.Histopathology2006; 48: 83–96.
2.
MucciariniC., RossiG., BertoliniF.. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.BMC Cancer2007; 7: 230.
3.
ChoS., KitadaiY., YoshidaS.. Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach.Int J Oncol2006; 28: 1361–7.
van der ZwanS.M., DeMatteoR.P.. Gastrointestinal stromal tumor: 5 years later.Cancer2005; 104: 1781–8.
8.
LasotaJ., JasinskiM., Sarlomo-RikalaM., MiettinenM.. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.Am J Pathol1999; 154: 53–60.
KindblomL.G., RemottiH.E., AldenborgF., Meis-KindblomJ.M.. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.Am J Pathol1998; 152: 1259–69.
11.
HirotaS., IsozakiK., MoriyamaY.. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.Science1998; 279: 577–80.
12.
De SilvaM.V.C., ReidR.. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD 117 expression, differential diagnosis and targeted cancer therapy with imatinib.Pathol Oncol Res2003; 9: 13–9.
SleijferS., WiemerE., SeynaeveC., VerweijJ.. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.Oncologist2007; 12: 719–26.
17.
BenjaminR.S., BlankeC.D., BlayJ., BonvalotS., EisenbergeB.. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.Oncologist2006; 11: 9–20.
18.
CohenM.H., DagherR., GriebelD.J.. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.Oncologist2002; 7: 393–400.
19.
BuchdungerE., ZimmermannJ., MettH.. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.Cancer Res1996; 56: 100–4.
20.
BuchdungerE., CioffiC.L., LawN.. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors.J Pharmacol Exp Ther2000; 295: 139–45.
21.
HeinrichM.C., GriffithD.J., DrukerB.J., WaitC.L., OttK.A., ZiglerA.J.. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.Blood2000; 96: 925–32.
22.
DrukerB.J., TalpazM., RestaD.J.. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med2001; 344: 1031–7.
23.
DrukerB.J., SawyersC.L., KantarjianH.. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med2001; 344: 1038–42.
24.
JoensuuH., RobertsP.J., Sarlomo-RikalaM.. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med2001; 344: 1052–6.
25.
Van OosteromA., JudsonI., VerweijJ.. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.Lancet2001; 358: 1421–3.
26.
DemetriG.D., von MehrenM., BlankeC.D.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med2002; 347: 472–80.
27.
HeinrichM.C., CorlessC.L., DemetriG.D.. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.J Clin Oncol2003; 21: 4342–9.
28.
BenjaminR., RankinC., FletcherC.. Phase III dose-randomized study of imatinib mesylate (IM) for GIST: Intergroup S0033 early results.Proc Am Soc Clin Oncol2003; 22: 814 (abst 3271).
29.
VerweijJ., CasaliP.G., ZalcbergJ.. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG.Proc Am Soc Clin Oncol2003; 22: 814 (abst 3272).
30.
VerweijJ., CasaliP.G., ZalcbergJ.. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: A randomised trial.Lancet2004; 364: 1127–34.
31.
WardelmannE., BüttnerR., Merkelbach-BruseS., SchildhausH.U.. Mutation analysis of gastrointestinal stromal tumours: increasing significance for risk assessment and effective targeted therapy.Virchows Arch2007; 451: 743–9.
32.
BlankeC.D., DemetriG.D., Von MehrenM.. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor patients treated with imatinib mesylate.Proc Am Soc Clin Oncol2006; 24: 526s.
Consensus meeting for the management of gastrointestinal stromal tumours.Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO.Ann Oncol2005; 16: 566–78.
GoldJ.S., DematteoR.P.. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.Ann Surg2006; 244: 176–84.
39.
MiettinenM., MajidiM., LasotaJ.. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.Eur J Cancer2002; 38(Suppl 5): S39–51.
40.
RossiC.R., MocellinS., MencarelliR.. Gastrointestinal stromal tumors: from a surgical to a molecular approach.Int J Cancer2003; 107: 171–6.
41.
NishidaT., HirotaS., TaniguchiM.. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.Nat Genet1998; 19: 323–4.
42.
ChompretA., KannengiesserC., BarroisM.. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.Gastroenterology2004; 126: 318–21.
43.
LevyA.D., RemottiH.E., ThompsonW.M., SobinL.H., MiettinenM.. Gastrointestinal stromal tumors: radiologic features with pathologic correlation.Radiographics2003; 23: 283–304.
44.
FullerC.E., WilliamsG.T.. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease).Histopathology1991; 19: 1–11.
45.
BoldoriniR., TosoniA., LeutnerM.. Multiple small intestinal stromal tumours in a patient with previously unrecognised neurofibromatosis type 1: immunohistochemical and ultrastructural evaluation.Pathology2001; 33: 390–5.
46.
CarneyJ.A., ShepsS.G., GoV.L.W., GordonH.. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma.N Engl J Med1977; 296: 1517–8.
47.
DeMatteoR.P., LewisJ.J., LeungD., MudanS.S., WoodruffJ.M., BrennanM.F.. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.Ann Surg2000; 231: 51–8.
FletcherC.D., BermanJ.J., CorlessC.. Diagnosis of gastrointestinal stromal tumors: a consensus approach.Hum Pathol2002; 33: 459–65.
51.
D'AmatoG., SteinertD.M., McAuliffeJ.C., TrentJ.C.. Update on the biology and therapy of gastrointestinal stromal tumors.Cancer Control2005; 12: 44–56.
52.
GoldJ.S., DeMatteoR.P.. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.Ann Surg2006; 244: 176–84.
53.
BeckersM.M.J., SleeP.H.T., van DoornJ.. Hypoglycaemia in a patient with a gastrointestinal stromal tumour.Clin Endocrinol (Oxf)2003; 59: 402–4.
54.
DubenecS.R., Dawes-HiggsE.K., HiggsR.J., TruskettP.G.. Haemoperitoneum caused by spontaneous rupture of a gastrointestinal stromal tumour.ANZ J Surg.2001; 71: 612–4.
55.
Cegarra-NavarroM.F., de la CalleM.A., Girela-BaenaE., García-SantosJ.M., Lloret-EstañF., de AndrésE.P.. Ruptured gastrointestinal stromal tumors: radiologic findings in six cases.Abdom Imaging2005; 30: 535–42.
56.
AjdukM., MikulicD., SebecicB.. Spontaneously ruptured gastrointestinal stromal tumor (GIST) of the jejunum mimicking acute appendicitis.Coll Antropol2004; 28: 937–41.
57.
BadalamentiG., RodolicoV., FulfaroF.. Gastrointestinal stromal tumors (GISTs): focus on pathological diagnosis and biomolecular features.Ann Oncol2007; 18(Suppl 6): vi136–40.
58.
RanchodM., KempsonR.L.. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: a pathologic analysis of 100 cases.Cancer1977; 39: 255–62.
59.
TzenC.Y., WangM.N., MauB.L.. Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors.Eur J Surg Oncol2008; 34: 563–8.
60.
AntonescuC., SommerG., SarranL.. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.Clin Cancer Res2003; 9: 3329–37.
61.
LasotaJ., Dansonka-MieszkowskaA., StachuraT.. Gastrointestinal stromal tumors with internal tandem duplications in 3 end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course.Mod Pathol2003; 16: 1257–64.
62.
MiettinenM., SobinL.H., MakloufH., LasotaJ.. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.Am J Surg Pathol2006; 30: 477–89.
63.
MartínJ., PovedaA., Llombart-BoschA.. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).J Clin Oncol2005; 23: 6190–8.
TaniguchiM., NishidaT., HirotaS.. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.Cancer Res1999; 59: 4297–300.
66.
MiettinenM., LasotaJ.. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.Virchows Archiv2001; 438: 1–12.
67.
PidhoreckyI., CheneyR.T., KraybillW.G., GibbsJ.F.. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.Ann Surg Oncol2000; 7: 705–12.
68.
EisenbergB.L., JudsonI.. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.Ann Surg Oncol2004; 11: 465–75.
69.
MiettinenM., El-RifaiW., SobinL.H., LasotaJ.. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.Hum Pathol2002; 33: 478–83.
70.
MiettinenM., LasotaJ.. Gastrointestinal stromal tumours: pathology and prognosis at different sites.Semin Diagn Pathol2006; 23: 70–83.
71.
AnderssonJ., BummingP., Meis-KindblomJ.M.. Gastrointestinal tumors with KIT exon 11 deletions are associated with poor prognosis.Gastroenterology2006; 131: 976–7.
72.
WardelmannE., LosenI., HansV.. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.Int J Cancer2003; 106: 887–95.
73.
LasotaJ., Dansonka-MieszkowskaA., SobinL.. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.Lab Invest2004; 84: 874–83.
74.
LasotaJ., StachuraJ., MiettinenM.. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology.Lab Invest2006; 86: 94–100.
75.
WardelmannE., HrychykA., Merkelbach-BruseS.. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors.J Mol Diagn2004; 6: 197–204.
76.
LasotaJ., WozniakA., Sarlomo-RikalaM.. Mutations in exon 9 and exon 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases.Am J Pathol2000; 157: 1091–5.
77.
MoskalukC.A., TianQ., MarshallC.R., RumpelC.A., FranquemontD.W., FriersonH.F.Jr. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors.Oncogene1999; 18: 1897–902.
78.
SingerS., RubinB.P., LuxM.L.. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.J Clin Oncol2002; 20: 3898–905.
79.
KimT.W., LeeH., KangY.K.. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors.Clin Cancer Res2004; 10: 3076–81.
80.
WongN.A., YoungR., MalcomsonR.D.. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.Histopathology2003; 43: 118–26.
81.
SakuraiS., FukasawaT., ChongJ.M.. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumors and interstitial cells of Cajal.Am J Pathol1999; 154: 23–8.
82.
NishidaT., HirotaS.. Biological and clinical review of stromal tumours in the gastrointestinal tract.Histol Histopathol2000; 15: 1293–301.
83.
LiuF.Y., QiJ.P., XuF.L., WuA.P.. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor.World J Gastroenterol2006; 12: 4161–5.
84.
ChanJ.. Mesenchymal tumors of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT).Implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anat Pathol1999; 6: 19–40.
85.
MiettinenM., MonihanJ.M., Sarlomo-RikalaM.. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases.Am J Surg Pathol1999; 23: 1109–18.
86.
WangL., VargasH., FrenchS.W.. Cellular origin of gastrointestinal stromal tumors: a study of 27 cases.Arch Pathol Lab Med2000; 124: 1471–5.
87.
Sarlomo-RikalaM., KovatichA.J., BaruseviciusA., MiettinenM.. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34.Mod Pathol1998; 11: 728–34.
88.
HeinrichM.C., RubinB.P., LongleyB.J., FletcherJ.A.. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.Hum Pathol2002; 33: 484–95.
89.
TornilloL., TerraccianoL.M.. An update on molecular genetics of gastrointestinal stromal tumours.J Clin Pathol2006; 59: 557–63.
90.
BesmerP., MurphyJ.E., GeorgeP.C.. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family.Nature1986; 320: 415–21.
91.
QiuF.H., RayP., BrownK.. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus.EMBO J1988; 7: 1003–11.
92.
BesmerP.. The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor.Curr Opin Cell Biol1991; 3: 939–46.
93.
SandersK.M., OrdogT., KohS.D., TorihashiS., WardS.M.. Development and plasticity of interstitial cells of Cajal.Neurogastroenterol Motil1999; 11: 311–38.
94.
AshmanL.K.. The biology of stem cell factor and its receptor C-kit.Int J Biochem Cell Biol1999; 31: 1037–51.
95.
LongleyB.J., RegueraM.J., MaY.. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.Leuk Res2001; 25: 571–6.
96.
SommerG., AgostiV., EhlersI.. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.Proc Natl Acad Sci USA2003; 100: 6706–711.
97.
RubinB.P., SingerS., TsaoC.. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.Cancer Res2001; 61: 8118–21.
98.
MiettinenM., SobinL.H., LasotaJ.. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical and molecular genetic study of 1765 cases with long-term follow-up.Am J Surg Pathol2005; 29: 52–68.
MaY., CunninghamM.E., WangX., GhoshI., ReganL., LongleyB.J.. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region.J Biol Chem1999; 19: 13399–402.
101.
SakuraiS., OguniS., HironakaM., FukayamaM., MorinagaS., SaitoK.. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese.Jpn J Cancer Res2001; 92: 494–8.
102.
KinoshitaK., IsozakiK., HirotaS.. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors.J Gastroenterol Hepatol2003; 18: 147–51.
103.
WardelmannE., NeidtI., BierhoffE.. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.Mod Pathol2002; 15: 125–36.
104.
HirotaS., OhashiA., NishidaT.. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.Gastroenterology2003; 125: 660–7.
105.
CorlessC.L., SchroederA., GriffithD.. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.J Clin Oncol2005; 23: 5357–64.
WardelmannE., PaulsK., Merkelbach-BruseS.. Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype.Verh Dtsch Ger Pathol2004; 88: 174–83.
108.
HeinrichM.C., ShoemakerJ.S., CorlessC.L.. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+).J Clin Oncol (Meeting Abstracts)2005; 23: 7.
109.
AgaramN.P., BesmerP., WongG.C.. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.Clin Cancer Res2007; 13: 170–81.
110.
Debiec-RychterM., SciotR., Le CesneA.. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Eur J Cancer2006; 42: 1093–103.
111.
RutkowskiP., NoweckiZ.I., Debiec-RychterM.. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).J Cancer Res Clin Oncol2007; 133: 589–97.
112.
PrenenH., CoolsJ., MentensN.. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.Clin Cancer Res2006; 12: 2622–7.
113.
Debiec-RychterM., CoolsJ., DumezH.. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of PKC412 inhibitor against imatinib-resistant mutants.Gastroenterology2005; 128: 270–9.
114.
HeinrichM.C., CorlessC., BlankeC.D.. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.J Clin Oncol2006; 24: 4764–74.
115.
MaY., ZengS., MetcalfeD.D.. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.Blood2002; 99: 1741–4.
116.
ZermatiY., De SepulvedaP., FegerF.. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.Oncogene2003; 22: 660–4.
117.
DaubH., SpechtK., UllrichA.. Strategies to overcome resistance to targeted protein kinase inhibitors.Nat Rev Drug Discov2004; 3: 1001–10.
118.
MolC.D., FabbroD., HosfieldD.J.. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.Curr Opin Drug Discov Devel2004; 7: 639–48.
119.
ChenL.L., TrentJ.C., WuE.F.. A missense mutation mutation in kit kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.Cancer Res2004; 64: 5913–9.
120.
AntonescuC.R., BesmerP., GuoT.. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation.Clin Cancer Res2005; 11: 4182–90.
121.
TamboriniE., BonadimanL., GrecoA.. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Gastroenterology2004; 127: 294–9.
122.
WardelmannE., Merkelbach-BruseS., PaulsK.. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.Clin Cancer Res2006; 12: 1743–9.
123.
HohenbergerP., ReichardtP., GebauerB., WardelmannE.. Gastrointestinal stromal tumors (GIST)—current concepts of surgical management.Dtsch Med Wochenschr2004; 129: 1817–20.
124.
Van GlabbekeM., VerweijJ., CasaliP.G.. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).Eur J Cancer2006; 42: 2277–85.
125.
GuetensG., De BoeckG., HighleyM., DumezH., Van OosteromA.T., de BruijnE.A.. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.J Chromatogr A2003; 1020: 27–34.
MatthewsB.D., WalshR.M., KercherK.W.. Laparoscopic vs open resection of gastric stromal tumors.Surg Endosc2002; 16: 803–7.
128.
DemetriG.D., BenjaminR.S., BlankeC.D.. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)—expansion and update of the NCCN clinical practice guidelines.J Natl Compr Netw2004; 2: S1–S26.
BucherP., VilligerP., EggerJ.F., BuhlerL.H., MorelP.. Management of gastrointestinal stromal tumors: from diagnosis to treatment.Swiss Med Wkly2004; 134: 145–53.
131.
Van den AbbeeleA.D., BadawiR.D.. Use of positron emission tomography in oncology and its potential role to asseses response to imatinib mesylate therapy in gastrointestinal stromal tumours (GISTs).Eur J Cancer2002; 38(Suppl 5): S60–5.
132.
MudanS.S., ConlonK.C., WoodruffJ.M., LewisJ.J., BrennanM.F.. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection.Cancer2000; 88: 66–74.
133.
DrukerB.J., TamuraS., BuchdungerE.. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med1996; 2: 561–6.
134.
ChoiH.. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model.Curr Oncol Rep2005; 7: 307–11.
135.
BenjaminR.S., ChoiH., MacapinlacH.A.. We should desist using RECIST, at least in GIST.J Clin Oncol2007; 25: 1760–4.
136.
JagerP.L., GietemaJ.A., van der GraafW.T.. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.Nucl Med Commun2004; 25: 433–8.
137.
De MatteoR., OwzarK., MakiR.. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Presented at ASCO meeting 2007.
138.
Van OosteromA.T., JudsonI.R., VerweijJ.. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumours: a report of the EORTC Soft Tissue and Bone Sarcoma Group.Eur J Cancer2002; 38(Suppl 5): S83–7.
139.
ScaifeC.L., HuntK.K., PatelS.R.. Is there a role for surgery in patients with “unresectable” cKIT+ GIST treated with imatinib mesylate?Am J Surg2003; 186: 665–9.
140.
DemetriG.D., BenjaminR.S., BlankeC.D.. NCCN Task Force report: management of patients with gastrointestinal stromal tumors (GIST)—update of the NCCN clinical practice guidelines.J Natl Compr Canc Netw2007; 5(Suppl 2): S1–29; quiz S30.
141.
RockE.P., GoodmanV., JiangJ.X.. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.Oncologist2007; 12: 107–13.
142.
DemetriG.D., van OosteromA.T., GarrettC.R.. Efficacy and safety of sunitinib in patients with advanced gastrointestinal tumours after failure of imatinib: a randomised controlled trial.Lancet2006; 368: 1329–38.
143.
PrenenH., GuetensG., de BoeckG.. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.Pharmacology2006; 77: 11–6.
144.
DemetriG.D., JoensuuH.. Systemic treatment of patients with gastrointestinal stromal tumor: current status and future opportunities.Eur J Cancer Suppl2008: 6 (I): 1–14.
145.
ReubiJ.C., KornerM., WaserB., MazzucchelliL., GuillouL.. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours.Eur J Nucl Med Mol Imaging2004; 31: 803–10.
